Teratogenic effects of Propylthiouracil on Swiss albino mice fetuses – A gross study

Samta Tiwari¹, S K Pandey², Anand Mishra³

¹Assistant Professor, Department of Anatomy, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, Uttar Pradesh, India, ²Professor and Head, Department of Anatomy, Heritage Institute of Medical Sciences, Varanasi, Uttar Pradesh, India, ³Professor, Department of Anatomy, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.

ABSTRACT

Background: Propylthiouracil is an antithyroid drug used to treat hyperthyroidism in pregnancy, as euthyroid state is necessary for optimal pregnancy outcome. Few reports of fetal anomalies are associated with propylthiouracil use as compared to other antithyroid drugs, having severe teratogenic profile. Aims and Objectives: The present study has been conducted to divulge the teratogenic profile of propylthiouracil by observing its gross effects on mice fetuses, as limited data are available despite extensive usage of drug in pregnancy. Materials and Methods: A 100 mg/kg body weight/day of propylthiouracil was orally administered to pregnant Swiss albino mice on the 6th, 7th, and 8th days of gestation (treated group), while distilled water was given orally to pregnant dams of the control group (same volume and for same duration). The fetuses were collected, weighed, and studied for gross abnormalities after sacrificing the pregnant dams on the 18th day of conception. Results: In the present study, the treated group shows reduction in various growth parameters (mean body weight, mean crown-rump length, etc.) depicting growth retardation, in comparison to the control group. On examination, engorged cutaneous vessels, external hemorrhage, and omphalocele were also observed in the treated group. Conclusion: As propylthiouracil is observed to have teratogenic outcome, hyperthyroidism during the first trimester must be treated with minimum effective dose of the drug.

Key words: Propylthiouracil; Hyperthyroidism; Teratogenic profile; Growth parameters

INTRODUCTION

Teratology is the science which deals with the study of anomalous growth and differentiation causing congenital malformations in fetus when a female is exposed to certain exogenous agents during pregnancy. Documentation of teratogenic potential of these agents is essential as they are producing huge burden on health expenditure and is a poor health indicator for any country, worldwide. Awareness about these agents would facilitate medical professionals and expecting mothers to curtail the fetal exposure, which help in reducing congenital abnormalities.¹

Propylthiouracil is an antithyroid thioureylene drug, belonging to the family of thionamides. Propylthiouracil and methimazole/carbimazole are the antithyroid drugs used for the treatment of hyperthyroidism in pregnancy. Propylthiouracil presently is considered the safest drug to treat hyperthyroidism during early pregnancy.² The most common cause of pregnancy-associated hyperthyroidism is Graves’ disease.³ The pathogenesis of Graves’ disease is the formation of autoantibodies against thyrotropin receptor resulting in excessive thyroid hormone secretion and goiter.⁴,⁵ Graves’ disease during pregnancy must be treated effectively, as it is crucial for desirable pregnancy results. Hyperthyroidism during pregnancy may cause concomitant increased maternal and fetal complications such as miscarriage, prematurity, low birth weight, fetal death, pre-eclampsia, and thyroid storm.⁶,⁷

Conventionally, propylthiouracil has been preferred over methimazole because transplacental passage was thought to be lower.⁸ For the reason that, a limited number of
cases of fetal anomalies are related with antenatal use of propylthiouracil, it has been presumed to have favorable teratogenic profile than methimazole and hence acclaimed its usage in pregnancy.\(^6,9\) However, propylthiouracil antenatal use is also been associated with birth defects, though small, since its introduction.\(^10-12\) Thus, it has been advised to restrict propylthiouracil use to the first trimester of pregnancy and later changed to methimazole, to abate maternal and fetal risks.\(^7,13-15\) Hence, the present study aims to discover out convincing data regarding its teratogenic profile by observing fetal gross abnormalities when drug is given during early period of organogenesis.

**Aims and objectives**

The present study has been conducted to divulge the teratogenic profile of propylthiouracil by observing its gross effects on mice fetuses, as limited data are available despite extensive usage of drug in pregnancy.

**MATERIALS AND METHODS**

After the prior approval of the Institute Animal Ethical Committee (No. Dean/2015/CAEC/989, dated January 19, 2015), the study was conducted in the Teratology laboratory of the Department of Anatomy, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.

Twenty-one adult female Swiss albino mice with average body weight of 20–25 g were studied. The animals were housed individually in departmental animal house under optimal conditions for breeding. To facilitate mating, female mice were shifted to the cages containing male mice of same stock in the evening (two male per female). The presence of vaginal plug on the following morning indicates pregnancy and was considered as “Day 0” of gestation.

The pregnant dams were allocated two separate groups, one “control” and another, “treated.” Propylthiouracil is commercially available as tablet, containing 50 mg of the drug. Average weight of mice was 20 g and the average dose was worked out per mice to be 100 mg/kg body weight/day, as higher doses were lethal to mice. The stock solution of propylthiouracil was prepared under sterile conditions by pounding the drug (50 mg tablet) and dissolving it in 5 ml of distilled water. Hence, 1 ml of stock solution contains 10 mg of drug. Therefore, the amount of stock solution calculated per mice was 0.2 ml which contains 2 mg of propylthiouracil. The treated group was given 2 mg (100 mg/kg body wt./day) of the drug (orally) from the stock solution (0.2 ml) while the control mice were given 0.2 ml distilled water (orally) on the 6th, 7th, and 8th day of gestation.

The pregnancy was terminated by sacrificing dams near term by cervical dislocation. A midline laparotomy was done to exteriorize the uterine horns. The photographs of uterine horns with its content were taken and the sacs were inspected for resorption sites. The fetuses of both groups were collected, blotted dry with blotting paper, and weighed. The crown-rump length (CRL) and tail length of the fetuses of both groups were recorded with the help of graph paper.

All collected fetuses of both groups were photographed for their general appearance and gross malformations. Each fetus of both the groups was photographed in the right lateral, left lateral and ventral views. Data for both groups were recorded for various fetal parameters, that is, body weight, CRL, tail length. The independent t-test, considering \(P<0.05\) significant, was used for statistical analysis with the help of SPSS, version 23.

**RESULTS**

There was no significant difference of weight gain in treated mother mice as compared to the control. The resorption in the treated group was found to be six out of 71 implantations (8.62%), whereas no resorption was observed in the control group (Table 1).

The difference between various growth parameters such as mean weight, mean CRL, and mean tail length of fetuses of the control and treated group was found to be statistically significant, as shown in Table 2.

The gross inspection of uterine horns in mother mice showed decreased number of fetuses in the treated group (Figure 1b) as compared to the control (Figure 1a). Resorption sites were observed in the uterine horns of treated mice (Figure 1c). On gross examination, the fetuses of the treated group showed growth retardation and engorged cutaneous vessels. There were engorged cutaneous vessels on trunk and dorsal aspect of forelimb, seen in the right lateral view of three treated cases (Figure 2a). In two cases, the engorged cutaneous vessels had been observed on dorsal aspect of the left forelimb. The generalized hemorrhagic areas were observed on the left lateral view, in four cases (Figure 2b). Similar findings had been found on the right lateral and ventral parts in

<table>
<thead>
<tr>
<th>Table 1: Pregnancy outcomes of both the control and treated groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Control</strong></td>
</tr>
<tr>
<td>Total number of mother mice</td>
</tr>
<tr>
<td>Implantation</td>
</tr>
<tr>
<td>Resorption</td>
</tr>
<tr>
<td>Live fetuses</td>
</tr>
</tbody>
</table>
same four cases. In one treated case, the ventral view showed absence of anterior abdominal wall (omphalocele) (Figure 2c). No such abnormalities were seen in the control group.

**DISCUSSION**

Propylthiouracil, a thionamide-derived antithyroid drug, has been used in the treatment of hyperthyroidism, in early period of pregnancy. As the reports from the previous studies were inconclusive regarding teratogenic effects of propylthiouracil, so this study was intended to see its teratogenic effect on pregnancy and fetus. In the present study, 100 mg/kg body weight of propylthiouracil was given to the pregnant Swiss albino mice during early period of organogenesis.

The present study showed that the propylthiouracil exposure during embryogenesis was associated with fetal loss, similar to a previous study. The present study also revealed decrease in litter size in more than 90% of cases and resorption was observed in 8.62% of cases in the treated group, differing from a previous study which showed no effect on litter size and resorption rates.

In a case–control study, increased risk of intrauterine growth retardation in women treated with propylthiouracil during pregnancy was observed. In the study done by Mallela et al., there were 2 experimental animals (mice and rat) and study of different doses for different antithyroid drugs and gestational age were done. In mice fetuses no abnormalities were observed while in rat fetuses abnormalities were found similar to present study. Similar study showed significant increase in CRL of mice fetuses when drug was given from gestation day 7–9, but significant decrease was observed when it was given from gestation day 3–7.

| Table 2: Fetal weight, crown-rump length, and tail length of fetuses (control and treated groups) |

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Mean</th>
<th>SD</th>
<th>S.E.</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal weight</td>
<td></td>
<td>1.42915</td>
<td>0.070838</td>
<td>0.011973</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Control</td>
<td>35</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treated</td>
<td>65</td>
<td>1.31530</td>
<td>0.230277</td>
<td>0.028562</td>
<td></td>
</tr>
<tr>
<td>Crown-rump length</td>
<td></td>
<td>2.38289</td>
<td>0.682560</td>
<td>0.115373</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Control</td>
<td>35</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treated</td>
<td>65</td>
<td>2.25538</td>
<td>1.862716</td>
<td>0.231041</td>
<td></td>
</tr>
<tr>
<td>Tail length</td>
<td></td>
<td>1.24653</td>
<td>0.48449</td>
<td>0.081886</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Control</td>
<td>35</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treated</td>
<td>65</td>
<td>1.17076</td>
<td>0.947415</td>
<td>0.117512</td>
<td></td>
</tr>
</tbody>
</table>

P<0.005 significant. N: No. of fetuses, SD: Standard deviation, S.E.: Standard error

**Figure 1:** Photographs of uterine horns (mother mice) in the control and treated groups. (a) Control uterine horns showing five fetuses (→) in the right and four fetuses (←) in the left uterine horns. (b) Treated uterine horns showing three fetuses (→) in the right and two fetuses (←) in the left uterine horns. (c) Treated uterine horns showing four resorption sites (→) on the right and two fetuses in the left horns (★)

**Figure 2:** Gross photographs of fetuses of the control and treated groups. (a) The right lateral view of control and treated fetuses. The treated fetus shows growth retardation with engorged cutaneous vessels on trunk and forelimb as compared to the control (→). (b) The left lateral view of control and treated fetuses. The treated fetus shows growth retardation and generalized hemorrhagic areas on trunk (→). (c) Ventral view of control and treated fetuses. The treated fetus shows the absence of anterior abdominal wall (omphalocele) (→)
A significant decrease in tail length of treated fetuses has also been observed in the present study, which was not revealed earlier, especially in mice fetuses. However, van Veenendaal et al., found wavy, short, and/or kinked tail in Xenopus embryos exposed to 1 mM of propylthiouracil. In the present study, engorged cutaneous vessels on forelimb and trunk of treated fetuses have been observed. Subcutaneous hemorrhages on trunk and hemorrhagic spots on snout and foot were also seen in treated mice fetuses. While in a previous study, subcutaneous hemorrhages on the trunk and leg along with focal hemorrhages at umbilicus and urinary bladder have been observed. In the same study, blood was found in various cavities such as nasal, oral, abdominal, and pleural cavities.

Several researchers documented gross defects such as anencephaly, cleft lip or palate, defective ear lobe, aplasia cutis congenita, and pre-auricular cyst/sinus in children exposed antenatally to propylthiouracil. While in a previous study, subcutaneous hemorrhages on the trunk and leg along with focal hemorrhages at umbilicus and urinary bladder have been observed. In the same study, blood was found in various cavities such as nasal, oral, abdominal, and pleural cavities.

Propylthiouracil can freely cross the placental barrier and may inhibit fetal thyroid function, which, in turn, may lead to intrauterine growth retardation, low birth weight, fetal hypothyroidism, and fetal thyroid dysfunction with or without goiter. All antithyroid drugs may inhibit fetal thyroid function causing fetal hypothyroidism. Propylthiouracil-induced hypo- or hyperthyroidism may be the probable cause of congenital anomalies as seen in the present study.

Yu et al., proposed that propylthiouracil was associated with ANCA (anti-neutrophil cytoplasmic antibody)-positive vasculitis and the presence of AECA (anti-endothelial cell antibodies). In the initial phase of ANCA-positive vasculitis, endothelial damage is a crucial phenomenon and AECA could induce endothelial damage by antibody-dependent cellular cytotoxicity. The damaged endothelium causes leakage of blood into intercellular spaces and engorged subcutaneous vessels. This may be correlated with the subcutaneous and focal hemorrhages found in the present study.

**Limitations of the study**

As this is an experimental animal study, the results cannot be directly extrapolated to human beings. Hence, there is need of large randomized clinical trial to ascertain the teratogenic potential of Propylthiouracil.

**CONCLUSION**

Propylthiouracil is used globally to treat pregnancy-associated hyperthyroidism, especially during the first trimester, as it has low toxicity profile compared to other available treatment modalities. However, the present study reported its teratogenic potential in developing fetus, especially in high dose.

Taking this result into consideration from present animal study, vigilant monitoring becomes obligatory for this drug. Based on various gross findings of the present study, propylthiouracil was found to be teratogenic at a dose of 100 mg/kg of body weight during early period of organogenesis. Propylthiouracil use cannot be completely evaded as treatment option in pregnant women with hyperthyroidism, thought it is associated with increased risk of fetal malformations. Hence, until safety of propylthiouracil is established, pregnancy-associated hyperthyroidism must be treated with minimal effective dose. This study also raises the necessity for a large randomized clinical trial of propylthiouracil or the search of a newer and safer treatment modality.

**ACKNOWLEDGMENT**

The authors would like to sincerely thank all the teaching and non-teaching faculty of Department of Anatomy, Institute of Medical Sciences, Banaras Hindu University for their support and pay homage to all the mice who lost their lives during the study in serving humanity.

**REFERENCES**

Metab. 2007;3(6):470-478. https://doi.org/10.1038/rncpendmet0508


8. Mortimer RH, Cannel GR, Addison RS, Johnson LP, Roberts MS and Bernus I. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab. 1997;82(9):3099-3102. https://doi.org/10.1210/jcem.82.9.4210


Authors Contribution:
ST- Concept and design of the study, prepared first draft of manuscript, statistical analysis, and interpretation; PSK- Interpreted the result, concept, and coordination; and AM- Reviewed the literature and revision of manuscript.

Work attributed to:
Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005, Uttar Pradesh, India.

Orcid ID:
Dr. Samta Tiwari - https://orcid.org/0000-0002-0275-0572
Prof. S K Pandey - https://orcid.org/0000-0003-0505-8052
Prof. Anand Mishra - https://orcid.org/0000-0003-4827-6581

Source of Support: Nil, Conflict of Interest: None declared.